A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

Study Summary

The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.

Conditions

Hepatic Impairment (HI)

Interventions / Drugs

Nemtabrutinib

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment32 participants

Primary Completion—

Lead SponsorMerck Sharp & Dohme LLC

Data Retrieved2026-04-11 02:55:36.205250+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.